Results of Diabetic Macular Edema Treatment Dependence on Adherence to Antiangiogenic Therapy in Real Clinical Practice
https://doi.org/10.52420/umj.24.2.44
EDN: EAERCO
Abstract
Relevance. Diabetes mellitus (DM) is a chronic disease that can lead to various complications, one of which is diabetic retinopathy (DR), which can occur in more than 30 % of diabetic patients and diabetic macular edema (DME), the most formidable complication of DR. DME results in loss of central vision and significantly reduces quality of life. There are several treatments for DR including laser retinal photocoagulation, intravitreal injections of antivasoproliferative drugs, dexamethasone implant, and vitreoretinal surgery.
The aim of the work is to evaluate long-term real results of diabetic macular edema treatment depending on adherence to anti-VEGF therapy in the ophthalmoendocrinological centre of Chelyabinsk city.
Materials and methods. 76 patients with DME (including 23/76 (30.3 %) men, 53/76 (69.7 %) women) aged 64.4 [61.8; 70.0] years. In the total sample of patients, type 1 DM was diagnosed in 13/76 (17.1 %) patients, type 2 DM — in 63/76 (82.9 %) patients; nonproliferative stage of DR occurred in 51/76 (67.1 %), proliferative — in 25/76 (32.9 %) patients.
Discussion. There was a significant increase in MCOS and a decrease in retinal thickness after 3 loading injections. Stabilization of morphometric and functional results was observed after the 5th injection.
Conclusion. The study shows that the efficacy of aflibercept treatment for DME is achieved with five loading injections and regular therapy. When the drug is not administered regularly, the improving effect is not achieved, which may lead to a negative attitude to treatment and withdrawal from further follow-up.
About the Authors
E. A. Drozdova
South Ural State Medical University; City Clinical Hospital No. 11
Russian Federation
Competing Interests:
Russian Federation
Elena A. Drozdova — Doctor of Sciences (Medicine), Professor, Head of the Department of Ophthalmology, South Ural SMU; Ophthalmologist, City Clinical Hospital No. 11.
Chelyabinsk
Competing Interests:
The authors declare the absence of obvious or potential conflict of interest
K. N. Dashenko
South Ural State Medical University; City Clinical Hospital No. 11
Russian Federation
Competing Interests:
Russian Federation
Ksenia N. Dashenko — Candidate of Sciences (Medicine), Assistant of the Department of Ophthalmology, South Ural SMU; Ophthalmologist, City Clinical Hospital No. 11.
Chelyabinsk
Competing Interests:
The authors declare the absence of obvious or potential conflict of interest
A. S. Kuznetsov
South Ural State Medical University; City Clinical Hospital No. 11
Russian Federation
Competing Interests:
Russian Federation
Andrey S. Kuznetsov — Senior Laboratory Technician of the Department of Ophthalmology, South Ural SMU; Ophthalmologist, City Clinical Hospital No. 11.
Chelyabinsk
Competing Interests:
The authors declare the absence of obvious or potential conflict of interest
T. T. Gezibeykov
South Ural State Medical University; City Clinical Hospital No. 11
Russian Federation
Competing Interests:
Russian Federation
Teodor T. Gezibeykov — Postgraduate Student of the Department of Ophthalmology, South Ural SMU; Ophthalmologist, City Clinical Hospital No. 11.
Chelyabinsk
Competing Interests:
The authors declare the absence of obvious or potential conflict of interest
References
1. Lipatov DV, Aleksandrova VK, Bessmertnaya EG, Tolkacheva AA, Smirnova NB, Chistyakov TA. Epidemiology and prevalence of diabetic retinopathy in Russia. Modern Technologies in Ophthalmology. 2024; 1(4):26–27. (In Russ.). DOI: https://doi.org/10.25276/2312-4911-2024-4-26-27.
2. Lipatov DV, Aleksandrova VK, Bessmertnaya EG, Tolkacheva AA, Smirnova NB, Chistyakov TA, et al. Epidemiology and prevalence of diabetic retinopathy in Russia — current state of the problem. Russian National Ophthalmology Forum. 2024;2(4):599–600. (In Russ.). EDN: https://www.elibrary.ru/JMVISS.
3. Ionkina IV, Zherebtsova OM, Grinev AG. Pathogenetic factors of formation of morphological forms of diabetic macular edema (literature review). Medical Science and Education of the Urals. 2020;21(3):131–135. (In Russ.). DOI: https://doi.org/10.36361/1814-8999-2020-21-3-131-135.
4. Fursova AJ, Chubar NV, Tarasov MS, Nikulich IF, Vasilieva MA, Gusarevich OG. Antiangiogenic therapy of diabetic macular oedema. From theory to clinical practice. Russian Annals of Ophthalmology. 2018; 134(2):12–22. (In Russ.). DOI: https://doi.org/10.17116/oftalma2018134212-22.
5. Amirov AN, Abdulaeva EA, Minkhuzina EL. Diabetic macular oedema: Epidemiology, pathogenesis, diagnosis, clinical picture, treatment. Kazan Medical Journal. 2015;96(1):70–76. (In Russ.). DOI: https://doi.org/10.17750/KMJ2015-070.
6. Vorob’eva IV. Modern approach to early diagnosis and pathogenetic treatment of diabetic retinopathy. Russian Annals of Ophthalmology. 2016;132(5):60–67. (In Russ.). DOI: https://doi.org/10.17116/oftalma2016132560-67.
7. Ionkina IV, Zherebtsova OM, Grinev AG. Clinico-anamnestic and morphological features of diabetic macular edema development. Modern Technologies in Ophthalmology. 2019;16(3):51–54. (In Russ.). DOI: https://doi.org/10.25276/2312-4911-2019-3-51-54.
8. Filippov VM, Petrachkov DV, Budzinskaya MV, Sidamonidze AL. Modern concepts of pathogenesis of diabetic retinopathy. Russian Annals of Ophthalmology. 2021;137(5–2):306–313. (In Russ.). DOI: https://doi.org/10.17116/oftalma2021137052306.
9. Budzinskaya MV, Lipatov DV, Pavlov VG, Petrachkov DV. Biomarkers of diabetic retinopathy. Diabetes Mellitus. 2020;23(1):88–94. (In Russ.). DOI: https://doi.org/10.14341/DM10045.
10. Bikbov MM, Zainullin RM, Kudoyarova KI, Kalanov MR. Efficacy of intravitreal dexamethasone implant as a starting monotherapy and when switching from an anti-VEGF drug in diabetic macular edema. Russian Annals of Ophthalmology. 2021;137(6):5–11. (In Russ.). DOI: https://doi.org/10.17116/oftalma20211370615.
11. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016; 123(11):2376–2385. DOI: https://doi.org/10.1016/j.ophtha.2016.07.032.
12. Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. The New England Journal of Medicine. 2015;372(13):1193–1203. DOI: https://doi.org/10.1056/nejmoa1414264.
13. Budzinskaya MV, Fursova AZh, Pedanova EK. Specific biomarkers of response to antiangiogenic therapy. Russian Annals of Ophthalmology. 2020;136(2):117–124. DOI: https://doi.org/10.17116/oftalma2020136021117.
14. Korobelnik J, Do D, Schmidt-Erfurth U, Boyer D, Holz F, Heier J, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254. DOI: https://doi.org/10.1016/j.ophtha.2014.05.006.
15. Mira F, Paulo M, Henriques F, Figueira J. Switch to aflibercept in diabetic macular edema patients unresponsive to previous anti‐VEGF therapy. Journal of Ophthalmology. 2017;2017:5632634. DOI: https://doi.org/10.1155/2017/5632634.
16. Santoro EY. Experience of using aflibercept in the treatment of diabetic macular oedema according to the standard protocol in real clinical practice. Russian Ophthalmological Journal. 2018;11(4):80–86. (In Russ.). DOI: https://doi.org/10.21516/2072-0076-2018-11-4-80-85.
17. Neroev VV. Modern aspects of diabetic retinopathy and diabetic macular oedema treatment. Annals of the Russian Academy of Medical Sciences. 2012;67(1):61–65. (In Russ.). DOI: https://doi.org/10.15690/vramn.v67i1.112.
18. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. DOI: https://doi.org/10.1159/000458539.
19. Petrachkov DV, Budzinskaya MV, Pavlov VG, Arzhukhanov DD. Primary response in patients with diabetic macular oedema to antiangiogenic therapy. Point of View. East — West. 2019;(2):25–28. (In Russ.). DOI: https://doi.org/10.25276/2410-1257-2019-2-25-28.
20. Bobykin EV. Modes of application of antiangiogenic therapy for the treatment of macular diseases in ophthalmology (literature review). Practical Medicine. 2018;16(5):104–111. (In Russ.). DOI: https://doi.org/10.32000/2072-1757-2018-16-5-104-111.
21. Faizrakhmanov RR. Anti-VEGF dosing regimen for neovascular age-related macular degeneration treatment. Russian Annals of Ophthalmology. 2018;134(6):107–115. (In Russ.). DOI: https://doi.org/10.17116/oftalma2018134061107.
22. Kovacs K, Marra KV, Yu G, Wagley S, Ma J, Teague GC, et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Investigative Ophthalmology & Visual Science. 2015;56(11):6523–6530. DOI: https://doi.org/10.1167/iovs.15-16793.
23. Diabetic Retinopathy Clinical Research Network; Writing Committee; Aiello LP, Beck RW, Bressler NM, Browning DJ, Chalam KV, Davis M, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118(12):E5–E14. DOI: https://doi.org/10.1016/j.ophtha.2011.09.058.
24. Kirilyuk ML, Ishchenko VA. Pathogenesis of diabetic retinopathy: A review of the literature. International Endocrinology Journal. 2019;15(7):567–575. (In Russ.). DOI: https://doi.org/10.22141/22240721.15.7.2019.186061.
25. Bressler SB, Ayala A, Bressler NM, Melia M, Qin H, Ferris FL 3rd, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmology. 2016; 134(3):278–285. DOI: https://doi.org/10.1001/jamaophthalmol.2015.5346.
Review
For citations:
Drozdova EA, Dashenko KN, Kuznetsov AS, Gezibeykov TT. Results of Diabetic Macular Edema Treatment Dependence on Adherence to Antiangiogenic Therapy in Real Clinical Practice. Ural Medical Journal. 2025;24(2):44–55. (In Russ.) https://doi.org/10.52420/umj.24.2.44. EDN: EAERCO
Views:
132
Email this article 